GSA Capital Partners’s CRISPR Therapeutics CRSP Stock Holding History

GSA Capital Partners’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-9,711	Closed	-$462K	–	1807
2026 Q1	$462K	Buy	+9,711	New	+$512K	0.03%	967
2025 Q2	–	Sell	-10,772	Closed	-$367K	–	1798
2025 Q1	$367K	Buy	+10,772	New	+$457K	0.03%	1012
2022 Q2	–	Sell	-5,909	Closed	-$371K	–	1451
2022 Q1	$371K	Buy	+5,909	New	+$371K	0.05%	736
2021 Q4	–	Sell	-2,647	Closed	-$296K	–	1459
2021 Q3	$296K	Buy	+2,647	New	+$332K	0.03%	1028
2020 Q1	–	Sell	-19,666	Closed	-$1.2M	–	1136
2019 Q4	$1.2M	Buy	+19,666	New	+$1.07M	0.14%	130
2018 Q2	–	Sell	-18,831	Closed	-$861K	–	1714
2018 Q1	$861K	Sell	18,831 -61,769	-77%	-$2.55M	0.05%	759
2017 Q4	$1.89M	Buy	+80,600	New	+$1.53M	0.12%	254

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GSK plc London $602M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

GSA Capital Partners's CRSP Position: Q2 2026 in Review

GSA Capital Partners sold out of CRISPR Therapeutics (CRSP) in Q2 2026, closing a stake of 9,711 shares — an estimated $462K sold.

GSA Capital Partners first reported a position in CRSP in Q4 2017 and held it in 7 quarters. The position peaked at $1.89M in Q4 2017. 521 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

GSA Capital Partners reported no remaining CRISPR Therapeutics position as of Q2 2026 after selling out during the quarter.
GSA Capital Partners sold 9,711 CRISPR Therapeutics shares in Q2 2026, an estimated $462K.
GSA Capital Partners first reported a position in CRISPR Therapeutics in Q4 2017 and held it in 7 quarters.
GSA Capital Partners's CRISPR Therapeutics position peaked at $1.89M in Q4 2017.
521 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.